Drug
TRIA-662
TRIA-662 is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
1
33%
Ph phase_1
2
67%
Phase Distribution
2
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 2Efficacy & side effects
1(33.3%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(3)
Detailed Status
Completed3
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 12 (66.7%)
Phase 21 (33.3%)
Trials by Status
completed3100%
Recent Activity
0 active trials
Showing 3 of 3
completedphase_1
The Safety of a Hypolipidemic Agent in Healthy Normal Volunteers
NCT01930240
completedphase_2
A Pilot Study to Evaluate the Lipid Effects of TRIA-662
NCT02008084
completedphase_1
Comparison of TRIA-662 500 mg and Niaspan 1000 mg in Healthy Male and Female Volunteers Under Fed Conditions
NCT01809301
Clinical Trials (3)
Showing 3 of 3 trials
NCT01930240Phase 1
The Safety of a Hypolipidemic Agent in Healthy Normal Volunteers
NCT02008084Phase 2
A Pilot Study to Evaluate the Lipid Effects of TRIA-662
NCT01809301Phase 1
Comparison of TRIA-662 500 mg and Niaspan 1000 mg in Healthy Male and Female Volunteers Under Fed Conditions
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3